UiPath - PATH Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UiPath in the last twelve months. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PATH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PATH, but not buy additional shares or sell existing shares.
View PATH analyst ratings or view top-rated stocks.

15 Wall Street research analysts have issued twelve-month price targets for UiPath's shares. Their PATH share price forecasts range from $14.00 to $27.50. On average, they expect the company's share price to reach $19.25 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for PATH or view top-rated stocks among Wall Street analysts.

UiPath's stock was trading at $12.71 on January 1st, 2023. Since then, PATH shares have increased by 31.8% and is now trading at $16.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 7th 2023.
View our PATH earnings forecast.

UiPath Inc. (NYSE:PATH) posted its quarterly earnings results on Wednesday, December, 8th. The healthcare company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.13. The healthcare company had revenue of $220.82 million for the quarter, compared to the consensus estimate of $209.23 million. UiPath had a negative net margin of 31.02% and a negative trailing twelve-month return on equity of 15.38%. UiPath's revenue for the quarter was up 49.9% compared to the same quarter last year.

ETFs with the largest weight of UiPath (NYSE:PATH) stock in their portfolio include ARK Autonomous Technology & Robotics ETF (ARKQ), ARK Innovation ETF (ARKK), ARK Fintech Innovation ETF (ARKF), ARK Next Generation Internation ETF (ARKW), TrueShares Technology, AI & Deep Learning ETF (LRNZ), Global X Robotics & Artificial Intelligence ETF (BOTZ), ARK Space Exploration & Innovation ETF (ARKX) and ProShares S&P Kensho Smart Factories ETF (MAKX).

UiPath issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $270.00 million-$272.00 million, compared to the consensus revenue estimate of $269.14 million.

(PATH) raised $990 million in an initial public offering (IPO) on Wednesday, April 21st 2021. The company issued 21,300,000 shares at a price of $43.00-$50.00 per share. Morgan Stanley, JPMorgan, BofA Securities, Credit Suisse, Barclays and Wells Fargo Securities served as the underwriters for the IPO and SMBC Nikko, BMO Capital Markets, Mizuho Securities USA, KeyBanc Capital Markets, TD Securities (USA), Truist SecuritiesCowen, Evercore Group, Macquarie Capital (USA), Nomura, RBC Capital Markets, Canaccord Genuity, D. A. Davidson & Co., Oppenheimer & Co. and Needham & Co. were co-managers.

UiPath trades on the New York Stock Exchange (NYSE) under the ticker symbol "PATH."

UiPath's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.92%), Alkeon Capital Management LLC (3.20%), Renaissance Technologies LLC (0.96%) and Geode Capital Management LLC (0.92%). Insiders that own company stock include Ashim Gupta, Brad Brubaker, Daniel Dines, East Fund 2013 Sca Sic Digital, Hitesh Ramani, Kimberly Hammonds, Laela Sturdy, Philippe Botteri, Rich Wong, Ted Kummert and Thomas Neergaard Hansen.
View institutional ownership trends.

Shares of PATH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PATH stock can currently be purchased for approximately $16.75.

UiPath (NYSE:PATH) has a market capitalization of $9.26 billion and generates $1.06 billion in revenue each year. The healthcare company earns $-328,350,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 2,863 workers across the globe.

UiPath's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The official website for the company is www.uipath.com. The healthcare company can be reached via phone at 844-432-0455 or via email at investor.relations@uipath.com.